Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127975951 | 12797595 | 1 | I | 20160926 | 20160930 | 20160930 | EXP | US-ASTRAZENECA-2016SF02679 | ASTRAZENECA | 0.00 | F | Y | 0.00000 | 20160930 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127975951 | 12797595 | 1 | PS | FASLODEX | FULVESTRANT | 1 | Intramuscular | N | 21344 | INJECTION | |||||||||
| 127975951 | 12797595 | 2 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | N | 21344 | INJECTION | |||||||||
| 127975951 | 12797595 | 3 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | N | 0 | CAPSULE | |||||||||
| 127975951 | 12797595 | 4 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | N | 0 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127975951 | 12797595 | 1 | Breast cancer |
| 127975951 | 12797595 | 2 | Oestrogen receptor positive breast cancer |
| 127975951 | 12797595 | 3 | Breast cancer |
| 127975951 | 12797595 | 4 | Oestrogen receptor positive breast cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127975951 | 12797595 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127975951 | 12797595 | Malignant neoplasm progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |